Study: Cholesterol was lowered with an oral PCSK9 inhibitor.

Published Date: 08 Mar 2023

A new study conducted by Baylor College of Medicine and presented at the American College of Cardiology Annual Scientific Session as well as the World Congress of Cardiology shows that an oral PCSK9 inhibitor called MK-0616...

Read Full News

Latest News

Discussing Findings on Secukinumab (Cosentyx) Efficacy Over 4 Years in HS, With Martina Porter, MD Martina Porter, MD

This interview highlights long-term, phase 3 data from the SUNSHINE and SUNRISE core and extension trials on secukinumab for hidradenitis suppurativa.

Tapinarof Shows Early, Sustained Benefits in Pediatric Atopic Dermatitis, With Druhan Howell, MD Druhan Howell, MD

At ACAAI 2025, Howell discussed sub-analytical data showing early itch and skin improvements with tapinarof cream in children with AD aged 2–17 years.

ARCADIA LTE: Long-term Nemolizumab Effective in Adolescents with Atopic Dermatitis

ARCADIA LTE: Long-term Nemolizumab Effective in Adolescents with Atopic Dermatitis

Skin of Color Savvy: A New Podcast Episode Following SOCS Media Day

Skin of Color Savvy: A New Podcast Episode Following SOCS Media Day

The HCPFive: Top News for Healthcare Providers from the Week of 11/16

The HCPFive: Top News for Healthcare Providers from the Week of 11/16

Mid Trial Update Released on Baricitinib for Frontal Fibrosing Alopecia

Mid Trial Update Released on Baricitinib for Frontal Fibrosing Alopecia

Todays Updates

This Week on NeurologyLive® — November 24, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Positive Phase 3 OCEANIC-STROKE Data Position Asundexian for Upcoming FDA Submission Marco Meglio

Encouraging data from the OCEANIC-STROKE study suggest that asundexian may soon join the therapeutic landscape for secondary stroke prevention as Bayer advances toward submission.

Progress with Emerging TYK2 Inhibitors for Psoriasis, With Benjamin Lockshin, MD Benjamin Lockshin, MD, FAAD

Benjamin Locksin speaks in this interview about his session titled ‘Encapsulating Progress With New and Emerging TYK2 Inhibitors for Psoriasis.’

Discussing Zasocitinib and Other TYK2 Inhibitors for Psoriasis, With Ronald Vender, MD Ronald Vender, MD

After his sessions on TYK2 Inhibitors for psoriasis and on palmoplantar pustulosis, Vender discussed several key insights in this interview.

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Todays Updates

This Week on NeurologyLive® — November 24, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Positive Phase 3 OCEANIC-STROKE Data Position Asundexian for Upcoming FDA Submission Marco Meglio

Encouraging data from the OCEANIC-STROKE study suggest that asundexian may soon join the therapeutic landscape for secondary stroke prevention as Bayer advances toward submission.

Progress with Emerging TYK2 Inhibitors for Psoriasis, With Benjamin Lockshin, MD Benjamin Lockshin, MD, FAAD

Benjamin Locksin speaks in this interview about his session titled ‘Encapsulating Progress With New and Emerging TYK2 Inhibitors for Psoriasis.’

Discussing Zasocitinib and Other TYK2 Inhibitors for Psoriasis, With Ronald Vender, MD Ronald Vender, MD

After his sessions on TYK2 Inhibitors for psoriasis and on palmoplantar pustulosis, Vender discussed several key insights in this interview.

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Latest News

This interview highlights long-term, phase 3 data from the SUNSHINE and SUNRISE core and extension trials on secukinumab for hidradenitis suppurativa.

At ACAAI 2025, Howell discussed sub-analytical data showing early itch and skin improvements with tapinarof cream in children with AD aged 2–17 years.

ARCADIA LTE: Long-term Nemolizumab Effective in Adolescents with Atopic Dermatitis

Skin of Color Savvy: A New Podcast Episode Following SOCS Media Day

The HCPFive: Top News for Healthcare Providers from the Week of 11/16

Mid Trial Update Released on Baricitinib for Frontal Fibrosing Alopecia

News All Time

New pill cuts 'bad' cholesterol by 60%, potentially replacing injections

A new pill from Merck could change how millions of people treat high cholesterol and help prevent heart attacks and strokes without the need for injections.

New gene discoveries improve diagnosis of inherited heart disease

Centenary Institute researchers have uncovered new genetic causes of inherited heart conditions, providing families with vital answers to guide treatment and prevention.

From contraception to menopause: Why women face a higher risk of stroke

Stroke is one of the leading causes of disability worldwide. It places a huge burden on families, health systems and societies. Increasingly, strokes are not just occurring in older adults. They are affecting younger people ...

Protein found to be key in blood vessel healing after surgical injury

Surgeons in the United States perform nearly 600,000 coronary artery stent procedures and bypass surgeries every year.

New pediatric basic life support guidelines seek to improve outcomes, optimize care, says co-author

While sudden cardiac arrest in a child or adolescent is rare—about 20,000 cases occur each year in the U.S.—the survival rate when it happens outside of a hospital is estimated to be under 20%. Significantly improving ...

Extending anti-clotting treatment linked to lower rates of new clots

Extending anti-clotting drugs beyond the initial treatment period of at least 90 days after a first blood clot is linked to lower rates of new clots developing compared with stopping treatment, finds a US study published ...

High blood pressure in children nearly doubled from 2000–2020, global study finds

The rate of children and adolescents experiencing high blood pressure worldwide nearly doubled between 2000 and 2020, according to a new meta-analysis published in The Lancet Child & Adolescent Health journal.

Q&A: How to have a heart-healthy Thanksgiving

Thanksgiving is a time to gather with loved ones, give thanks, and savor the flavors of the season. But for anyone striving to eat heart-healthy, the holiday can present some challenges. With buttery sides, decadent desserts, ...

'Humanized' model developed to study heart valve stiffness

The first ever "humanized" model for aortic valve calcification paves the way for testing potential treatments.

Very low LDL-cholesterol correlates to fewer heart problems after stroke

Brigham and Women's Hospital's TIMI Study Group reports that in patients with prior ischemic stroke, very low achieved LDL-cholesterol correlated with fewer major adverse cardiovascular events and fewer recurrent strokes, ...

Plant-based diet can prevent, reverse form of heart disease in animals with hypertension

Eating a plant-based diet consisting of fruits, vegetables, nuts and legumes can help prevent and reverse heart disease in rats that have high blood pressure, according to a study published by researchers in the Institute ...

Genetic testing trifecta predicts risk of sudden cardiac death and arrhythmia

In a new Northwestern Medicine study, scientists have developed a more precise genetic risk score to determine whether a person is likely to develop arrhythmia, an irregular heartbeat that can lead to serious conditions such ...

Effectiveness of anti-clotting meds after stent placement varied in people with diabetes

One year of dual antiplatelet therapy with one of two potent P2Y12 inhibitors—ticagrelor or prasugrel—in people with Type 1 or Type 2 diabetes who had received a drug-eluting stent did not offer the same level of benefit ...

LDL cholesterol improved among veterans in program with health coaches, other resources

A quality improvement program helped reduce "bad cholesterol" (LDL or low-density lipoprotein) levels among military veterans who have heart and blood vessel disease, according to a preliminary late-breaking science presentation ...

Researchers use AI and genetics to identify early signs of a rare, life-threatening heart condition

At Mayo Clinic, cardiologists Peter Noseworthy, M.D., and John Giudicessi, M.D., Ph.D., are uncovering the earliest signs of a genetic heart condition that often strikes without warning. Their work shows that early detection, ...

Sons of mothers with type 1 diabetes show early signs of vascular dysfunction

A new study from Karolinska Institutet and Stockholm University reveals that sons born to mothers with type 1 diabetes may develop early vascular dysfunction—independently of metabolic health. The finding may help shape ...

Recommended News For You

Urinary tract cancer prediction models with high sensitivity and specificity

Testosterone recovery linked to overall survival in high-risk prostate cancer

How to keep your prostate healthy and lower your risk of developing serious problems

PSMA PET Beats MRI in Prostate Cancer Staging Study

No increased risk of childhood cancer near UK nuclear sites, study finds

Cancer Patients Who Completed Medication Survey Received More Help From Pharmacists

Results for Prostate Cancer Are Associated With PSA Nadir 6 Months After Primary RT.

Recommended Articles For You

Therapeutic Innovations Through Germline Predisposition in Acute Leukemias and Myeloid Neoplasms 

Driving Impact: Oncology Pharmaceutical Marketing Strategies in the USA 

Case Study: Advancing Preclinical Oncology Drug Development with Quantitative Systems Pharmacology 

Breakthroughs in Cancer Care: From Rare Diagnoses to Advanced and Early-Stage Treatments 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Significant differences in breast cancer care still exist, but surgeons can change.

2.

A small rise in cancer was observed following the 1986 Chernobyl accident.

3.

Genetics and Genetic Testing to Inform Myelofibrosis Clinical Management.

4.

Researchers use AI to monitor side effects of chemotherapy and support families dealing with pediatric cancer.

5.

AI catches one-third of interval breast cancers missed at screening

1.

The Predictive Power of Theranostics in Palliative Neuroendocrine Tumor Management

2.

Unleashing the Power of AI: A Systematic Review of Predictive Biomarker Discovery in Immuno-Oncology

3.

An Overview Of Leukemia Cutis: What It Is And How To Treat It

4.

Oncolytic Viruses in Breast Cancer: Unlocking Synergy with Novel Combination Therapies

5.

Advancing Cancer Care: Insights into Oncology Trials, Immunotherapy, and CAR-T Innovations

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part I

2.

Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I

3.

The Landscape of First-Line Treatment for Urothelial Carcinoma- The Conclusion

4.

First Line Combination Therapy- The Overall Survival Data in NSCLC Patients

5.

Current Cancer Scenario in India- Importance of Genomic Testing & Advancement in Diagnosis and Treatment

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot